发明授权
US5840725A Substituted oximes, hydrazones and olefins as neurokinin antagonists
失效
取代的肟,腙和烯烃作为神经激肽拮抗剂
- 专利标题: Substituted oximes, hydrazones and olefins as neurokinin antagonists
- 专利标题(中): 取代的肟,腙和烯烃作为神经激肽拮抗剂
-
申请号: US901028申请日: 1997-07-25
-
公开(公告)号: US5840725A公开(公告)日: 1998-11-24
- 发明人: Gregory A. Reichard , Robert G. Aslanian , Cheryl A. Alaimo , Michael P. Kirkup , Andrew Lupo, Jr. , Pietro Mangiaracina , Kevin D. McCormick , John J. Piwinski , Bandarpalle B. Shankar , Neng-Yang Shih , James M. Spitler , Pauline C. Ting , Ashit Ganguly , Nicholas I. Carruthers
- 申请人: Gregory A. Reichard , Robert G. Aslanian , Cheryl A. Alaimo , Michael P. Kirkup , Andrew Lupo, Jr. , Pietro Mangiaracina , Kevin D. McCormick , John J. Piwinski , Bandarpalle B. Shankar , Neng-Yang Shih , James M. Spitler , Pauline C. Ting , Ashit Ganguly , Nicholas I. Carruthers
- 申请人地址: NJ Kenilworth
- 专利权人: Schering Corporation
- 当前专利权人: Schering Corporation
- 当前专利权人地址: NJ Kenilworth
- 主分类号: C07D295/12
- IPC分类号: C07D295/12 ; A61K31/397 ; A61K31/40 ; A61K31/415 ; A61K31/4178 ; A61K31/439 ; A61K31/4427 ; A61K31/443 ; A61K31/4433 ; A61K31/4436 ; A61K31/445 ; A61K31/4465 ; A61K31/4468 ; A61K31/45 ; A61K31/451 ; A61K31/452 ; A61K31/4523 ; A61K31/4525 ; A61K31/454 ; A61K31/4545 ; A61K31/47 ; A61K31/4709 ; A61K31/495 ; A61K31/496 ; A61K31/497 ; A61K31/501 ; A61K31/505 ; A61K31/506 ; A61K31/535 ; A61K31/5375 ; A61K31/5377 ; A61P1/00 ; A61P11/00 ; A61P25/00 ; A61P29/00 ; A61P43/00 ; C07D205/04 ; C07D207/08 ; C07D207/12 ; C07D207/14 ; C07D211/52 ; C07D211/58 ; C07D211/76 ; C07D295/13 ; C07D295/185 ; C07D333/22 ; C07D401/04 ; C07D401/06 ; C07D401/12 ; C07D401/14 ; C07D403/04 ; C07D405/12 ; C07D409/06 ; C07D413/06 ; C07D413/12 ; C07D413/14 ; C07D417/12 ; C07D451/04 ; C07D403/06
摘要:
Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or3; b, d and e are independently 0, 1 or 2; R is H, C.sub.1-6 alkyl, --OH or C.sub.2 -C.sub.6 hydroxyalkyl; A is an optionally substituted oxime, hydrazone or olefin; X is a bond, --C(O)--, --O--, --NR.sup.6 --, --S(O)e--, --N(R.sup.6)C(O)--, --C(O)N(R.sup.6)-- --OC(O)NR.sup.6 --, --OC(.dbd.S)NR.sup.6 --, --N(R.sup.6)C(.dbd.S)O--, --C(.dbd.NOR.sup.1)--, --S(O).sub.2 N(R.sup.6)--, --N(R.sup.6)S(O).sub.2 --, --N(R.sup.6)C(O)O-- or --OC(O)--;T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl; Q is --SR.sup.6, --N(R.sup.6)(R.sup.7), --OR.sup.6, phenyl, naphthyl or heteroaryl; R.sup.6a, R.sup.7a, R.sup.8a, R.sup.9a, R.sup.6 and R.sup.7 are H, C.sub.1-6 alkyl, C.sub.2 -C.sub.6 hydroxyalkyl, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkyl, phenyl or benzyl; or R.sup.6 and R.sup.7, together with the nitrogen to which they are attached, form a ring; R.sup.9a is R.sup.6 or --OR.sup.6 ; Z is morpholinyl, optionally N-substituted piperazinyl, optionally substituted ##STR2## or substituted ##STR3## g is 0-3 and h is 1-4, provided the sum of h and g is 1-7; wherein aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted; methods of treating asthma, cough, bronchospasm, imflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.
公开/授权文献
- US5999325A Optical device and method of manufacturing the same 公开/授权日:1999-12-07